Erythromycin Estolate (BioDeep_00001868116)
Main id: BioDeep_00000015028
Chemicals and Drugs
代谢物信息卡片
Erythromycin Estolate
化学式: C40H71NO14.C12H26O4S (1055.6426022)
中文名称: 依托红霉素
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCCCCCCCOS(=O)(=O)O.CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O
InChI: /m1./s1
描述信息
D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents
C784 - Protein Synthesis Inhibitor > C261 - Macrolide Antibiotic
C254 - Anti-Infective Agent > C258 - Antibiotic
D005765 - Gastrointestinal Agents
Erythromycin estolate, erythromycin derivative[1], is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport[2].
同义名列表
2 个代谢物同义名
数据库引用编号
15 个数据库交叉引用编号
- ChEBI: CHEBI:4846
- KEGG: C08031
- KEGGdrug: D70256
- KEGGdrug: D00851
- PubChem: 441371
- ChEMBL: CHEMBL2218877
- MeSH: Erythromycin Estolate
- CAS: 3521-62-8
- MetaboLights: MTBLC4846
- PubChem: 10231
- LipidMAPS: LMPK04000015
- NIKKAJI: J383.158B
- RefMet: Erythromycin estolate
- medchemexpress: HY-N7121
- KNApSAcK: 4846
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xiaohuan Wang, Yongkang Chen, Huichun Shi, Peng Zou. Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle.
Frontiers in cellular and infection microbiology.
2022; 12(?):905248. doi:
10.3389/fcimb.2022.905248. [PMID: 35873167] - Xiaoyan Lu, Yu Tian, Xueping Lian, Yachao Jin, Tingting Jin, Qinqin Zhao, Bin Hu, Xiuping Shen, Xiaohui Fan. Integrated systems toxicology approaches identified the possible involvement of ABC transporters pathway in erythromycin estolate-induced liver injury in rat.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
2014 Mar; 65(?):343-55. doi:
10.1016/j.fct.2013.12.050. [PMID: 24412560] - Sarah Dawson, Simone Stahl, Nikki Paul, Jane Barber, J Gerald Kenna. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Jan; 40(1):130-8. doi:
10.1124/dmd.111.040758. [PMID: 21965623] - G A Albarellos, V E Kreil, L A Ambros, S Waxman, L Montoya, L Tarragona, P C Quaine, R E Hallu, M Rebuelto. Pharmacokinetics of erythromycin after the administration of intravenous and various oral dosage forms to dogs.
Journal of veterinary pharmacology and therapeutics.
2008 Dec; 31(6):496-500. doi:
10.1111/j.1365-2885.2008.00982.x. [PMID: 19000270] - Pidaran Murugan, Leelavinothan Pari. Effect of tetrahydrocurcumin on erythromycin estolate-induced lipid peroxidation in rats.
Journal of basic and clinical physiology and pharmacology.
2005; 16(1):1-15. doi:
10.1515/jbcpp.2005.16.1.1. [PMID: 16187483] - L Pari, P Murugan. Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity.
Pharmacological research.
2004 May; 49(5):481-6. doi:
10.1016/j.phrs.2003.11.005. [PMID: 14998559] - Leelavinothan Pari, Arokiasamy Uma. Protective effect of Sesbania grandiflora against erythromycin estolate-induced hepatotoxicity.
Therapie.
2003 Sep; 58(5):439-43. doi:
10.2515/therapie:2003071. [PMID: 14682193] - J P Lavoie, R Drolet, D Parsons, R Leguillette, R Sauvageau, J Shapiro, L Houle, G Hallé, C J Gebhart. Equine proliferative enteropathy: a cause of weight loss, colic, diarrhoea and hypoproteinaemia in foals on three breeding farms in Canada.
Equine veterinary journal.
2000 Sep; 32(5):418-25. doi:
10.2746/042516400777591110. [PMID: 11037264] - J Lakritz, W D Wilson, A E Marsh, J E Mihalyi. Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
American journal of veterinary research.
2000 Aug; 61(8):914-9. doi:
10.2460/ajvr.2000.61.914. [PMID: 10951982] - S Venkateswaran, L Pari, P Viswanathan, V P Menon. Protective effect of Livex, a herbal formulation against erythromycin estolate induced hepatotoxicity in rats.
Journal of ethnopharmacology.
1997 Aug; 57(3):161-7. doi:
10.1016/s0378-8741(97)00062-7. [PMID: 9292408] - H Potthast, B Schug, M Elze, R Schwerdtle, H Blume. [Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state].
Die Pharmazie.
1995 Jan; 50(1):56-60. doi:
. [PMID: 7886126] - P Villa, D Cova, L De Francesco, A Guaitani, G Palladini, R Perego. Protective effect of diosmetin on in vitro cell membrane damage and oxidative stress in cultured rat hepatocytes.
Toxicology.
1992; 73(2):179-89. doi:
10.1016/0300-483x(92)90101-j. [PMID: 1609428] - J C Davila, A Lenherr, D Acosta. Protective effect of flavonoids on drug-induced hepatotoxicity in vitro.
Toxicology.
1989 Aug; 57(3):267-86. doi:
10.1016/0300-483x(89)90116-9. [PMID: 2756528] - C Stubbs, I Kanfer. Variability in the absorption and disposition of erythromycin estolate in humans.
Journal of pharmaceutical sciences.
1989 Aug; 78(8):635-8. doi:
10.1002/jps.2600780807. [PMID: 2778669] - D Bérubé, D Kirouac, D Croteau, M G Bergeron, M Lebel. Plasma bactericidal activity after administration of erythromycin estolate and erythromycin ethylsuccinate to healthy volunteers.
Antimicrobial agents and chemotherapy.
1988 Aug; 32(8):1227-30. doi:
10.1128/aac.32.8.1227. [PMID: 3142349] - D Croteau, M G Bergeron, M LeBel. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.
Antimicrobial agents and chemotherapy.
1988 Apr; 32(4):561-5. doi:
10.1128/aac.32.4.561. [PMID: 3259856] - D Croteau, F Vallée, M G Bergeron, M LeBel. High-performance liquid chromatographic assay of erythromycin and its esters using electrochemical detection.
Journal of chromatography.
1987 Aug; 419(?):205-12. doi:
10.1016/0378-4347(87)80278-5. [PMID: 3499443] - L C Swayne, J Kolc. Erythromycin hepatotoxicity. A rare cause of a false-positive technetium-99m DISIDA study.
Clinical nuclear medicine.
1986 Jan; 11(1):10-2. doi:
NULL. [PMID: 3943237] - G B Gaeta, R Utili, L E Adinolfi, C O Abernathy, G Giusti. Characterization of the effects of erythromycin estolate and erythromycin base on the excretory function of the isolated rat liver.
Toxicology and applied pharmacology.
1985 Sep; 80(2):185-92. doi:
10.1016/0041-008x(85)90074-2. [PMID: 2992120] - P Villa, J M Bégué, A Guillouzo. Erythromycin toxicity in primary cultures of rat hepatocytes.
Xenobiotica; the fate of foreign compounds in biological systems.
1985 Aug; 15(8-9):767-73. doi:
10.3109/00498258509047439. [PMID: 4072263] - C M Ginsburg, G H McCracken, S D Crow, B R Dildy, G Morchower, J B Steinberg, K Lancaster. Seroepidemiology of the group-A streptococcal carriage state in a private pediatric practice.
American journal of diseases of children (1960).
1985 Jun; 139(6):614-7. doi:
10.1001/archpedi.1985.02140080084039. [PMID: 3890522] - J Henry, P Turner, M Garland, F Esmieu. Plasma and salivary concentrations of erythromycin after administration of three different formulations.
Postgraduate medical journal.
1980 Oct; 56(660):707-10. doi:
10.1136/pgmj.56.660.707. [PMID: 7220406] - A R DiSanto, K Y Tserng, D J Chodos, K A DeSante, K S Albert, J G Wagner. Comparative bioavailability evaluation of erythromycin base and its salts and esters. I. Erythromycin estolate capsules versus enteric-coated erythromycin base tablets.
Journal of clinical pharmacology.
1980 Jul; 20(7):437-43. doi:
10.1002/j.1552-4604.1980.tb01716.x. [PMID: 7430412] - W M Selenke, G W Leung, R G Townley. Nonantibiotic effects of macrolide antibiotics of the oleandomycin-erythromycin group with special reference to their "steroid-sparing" effects.
The Journal of allergy and clinical immunology.
1980 Jun; 65(6):454-64. doi:
10.1016/0091-6749(80)90239-0. [PMID: 6966289] - C A Dujovne, A S Salhab. Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems.
Pharmacology.
1980; 20(6):285-91. doi:
10.1159/000137382. [PMID: 7403251] - D Krowchuk, J H Seashore. Complete biliary obstruction due to erythromycin estolate administration in an infant.
Pediatrics.
1979 Dec; 64(6):956-8. doi:
NULL. [PMID: 514726] - C W Derrick, H C Dillon. Streptococcal pharyngitis therapy. A comparison of two erythromycin formulations.
American journal of diseases of children (1960).
1979 Nov; 133(11):1146-8. doi:
10.1001/archpedi.1979.02130110054008. [PMID: 389036] - P G Welling, R L Elliott, M E Pitterle, H P Corrick-West, L L Lyons. Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.
Journal of pharmaceutical sciences.
1979 Feb; 68(2):150-5. doi:
10.1002/jps.2600680208. [PMID: 423080] - R Drew, B G Piestly. Effect of chlorpromazine and erythromycin on bile salt-induced cholestasis in the rat.
Pharmacology.
1979; 18(4):202-9. doi:
10.1159/000137253. [PMID: 572556] - W M McCormack, H George, A Donner, L F Kodgis, S Alpert, E W Lowe, E H Kass. Hepatotoxicity of erythromycin estolate during pregnancy.
Antimicrobial agents and chemotherapy.
1977 Nov; 12(5):630-5. doi:
10.1128/aac.12.5.630. [PMID: 21610] - S T Brown, H B Pedersen, K K Holmes. Comparison of erythromycin base and estolate in gonococcal urethritis.
JAMA.
1977 Sep; 238(13):1371-3. doi:
. [PMID: 408522] - C M Ginsburg, G H McCracken, M C Culbertson. Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions.
The Journal of pediatrics.
1976 Dec; 89(6):1011-3. doi:
10.1016/s0022-3476(76)80622-1. [PMID: 792404] - K Y Tserng, J G Wagner. Fluorometric determination of erythromycin and erythromycin propionate in whole blood or plasma and correlation of results with microbiological assay.
Analytical chemistry.
1976 Feb; 48(2):348-53. doi:
10.1021/ac60366a033. [PMID: 1247163] - P Männistö, J Tuomisto, R Räsänen. Absorption of erythromycin. A cross-over study in healthy volunteers.
Arzneimittel-Forschung.
1975 Nov; 25(11):1828-31. doi:
NULL. [PMID: 1106445] - P J Murphy, T L Williams, R E McMahon, R E Crabtree, A S Ridolfo. Metabolism of propionyl erythromycin lauryl sulfate. II. Fate of the lauryl sulfate moiety in the rat and man.
Drug metabolism and disposition: the biological fate of chemicals.
1975 May; 3(3):164-70. doi:
NULL. [PMID: 238815] - P J Murphy, T L Williams, R E McMahon, F J Marshall. Metabolism of propionyl erythromycin lauryl sulfate. I. Fate of the propionyl erythromycin moiety in the rat.
Drug metabolism and disposition: the biological fate of chemicals.
1975 May; 3(3):155-63. doi:
NULL. [PMID: 238814]